High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children

Ghyslain Mombo-Ngoma, Sunny Oyakhirome, Rosalynn Ord, Julian J Gabor, Katja C Greutélaers, Katharina Profanter, Benedikt Greutélaers, Florian Kurth, Bertrand Lell, Jürgen F J Kun, Saadou Issifou, Cally Roper, Peter G Kremsner, Martin P Grobusch, Ghyslain Mombo-Ngoma, Sunny Oyakhirome, Rosalynn Ord, Julian J Gabor, Katja C Greutélaers, Katharina Profanter, Benedikt Greutélaers, Florian Kurth, Bertrand Lell, Jürgen F J Kun, Saadou Issifou, Cally Roper, Peter G Kremsner, Martin P Grobusch

Abstract

Background: Drug resistance contributes to the global malaria burden. Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) polymorphisms confer resistance to sulphadoxine-pyrimethamine (SP).

Methods: The study assessed the frequency of SP resistance-conferring polymorphisms in Plasmodium falciparum-positive samples from two clinical studies in Lambaréné. Their role on treatment responses and transmission potential was studied in an efficacy open-label clinical trial with a 28-day follow-up in 29 children under five with uncomplicated malaria.

Results: SP was well tolerated by all subjects in vivo. Three subjects were excluded from per-protocol analysis. PCR-corrected, 12/26 (46%) achieved an adequate clinical and parasitological response, 13/26 (50%) were late parasitological failures, while 1/26 (4%) had an early treatment failure, resulting in early trial discontinuation. Of 106 isolates, 98 (92%) carried the triple mutant dhfr haplotype. Three point mutations were found in dhps in a variety of haplotypic configurations. The 437G + 540E double mutant allele was found for the first time in Gabon.

Conclusions: There is a high prevalence of dhfr triple mutant with some dhps point mutations in Gabon, in line with treatment failures observed, and molecular markers of SP resistance should be closely monitored.

Trial registration: ClinicalTrials.gov NCT00453856.

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. Greenwood BM, Bojang K, Whitty CJM, Targett GAT. Malaria. Lancet. 2005;365:1487–1498. doi: 10.1016/S0140-6736(05)66420-3.
    1. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductasethymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA. 1988;85:9109–9113. doi: 10.1073/pnas.85.23.9109.
    1. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA. 1988;85:9114–9118. doi: 10.1073/pnas.85.23.9114.
    1. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994;224:397–405. doi: 10.1111/j.1432-1033.1994.00397.x.
    1. Triglia T, Cowman AF. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci USA. 1994;91:7149–7153. doi: 10.1073/pnas.91.15.7149.
    1. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, Chandramohan D, Sharp B. Antifolate antimalarial resistance in southeast Africa: A population-based analysis. Lancet. 2003;361:1174–1181. doi: 10.1016/S0140-6736(03)12951-0.
    1. Schellenberg D, Kahigwa E, Drakeley C, Malenda A, Wigayi J, Msokame C, Aponte JJ, Tanner M, Mshinda H, Menendez C, Alonso PL. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2002;67:17–23.
    1. Mockenhaupt FP, Ehrhardt S, Dzisi SY, Teun Bousema J, Wassilew N, Schreiber J, Anemana SD, Cramer Jakob P, Otchwemah RN, Sauerwein RW, Eggelte TA, Bienzle U. A randomised, placebo-controlled, and double-blind trial on sulfadoxinepyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health. 2005;10:512–520. doi: 10.1111/j.1365-3156.2005.01427.x.
    1. Abacassamo F, Enosse S, Aponte JJ, Gómez-Olive FX, Quintó L, Mabunda S, Barreto A, Magnussen P, Ronn AM, Thompson R, Alonso PL. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambiquan children with noncomplicated malaria. Trop Med Int Health. 2004;9:200–208. doi: 10.1046/j.1365-3156.2003.01182.x.
    1. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JG, Lang T, Missinou MA, Mkandala C, Oduola AM, Premji Z, Robertson L, Sowunmi A, Ward SA, Winstanley PA. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 2004;363:1843–1848. doi: 10.1016/S0140-6736(04)16350-2.
    1. Oduro AR, Anyorigiya T, Hodgson A, Ansah P, Anto F, Ansah NA, Atuguba F, Mumuni G, Amankwa J. A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Trop Med Int Health. 2005;10:279–284. doi: 10.1111/j.1365-3156.2004.01382.x.
    1. Kremsner PG, Krishna A. Antimalarial combinations. Lancet. 2004;364:285–294. doi: 10.1016/S0140-6736(04)16680-4.
    1. Grobusch MP, Egan A, Gosling RD, Newman RD. Intermittent preventive therapy for malaria: Progress and future directions. Curr Opin Infect Dis. 2007;20:613–620. doi: 10.1097/QCO.0b013e3282f1ae3b.
    1. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C. Intermittent Preventive Treatment for malaria control in African Infants: Pooled analysis of safety and efficacy in six randomized controlled trials. Lancet. 2009;374:1533–1542. doi: 10.1016/S0140-6736(09)61258-7.
    1. WHO. Policy recommendation on Intermittent Preventive Treatment during infancy with sulfadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. World Health Organization, Geneva; 2010. [last accessed on 2 December 2010]
    1. Wernsdorfer WH, Noedl H. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis. 2003;16:553–558. doi: 10.1097/00001432-200312000-00007.
    1. Pearce RJ, Pota H, Evehe MS, Bâel H, Mombo-Ngoma G, Malisa AL, Ord R, Inojosa W, Matondo A, Diallo DA, Mbacham W, van den Broek IV, Swarthout TD, Getachew A, Dejene A, Grobusch MP, Njie F, Dunyo S, Kweku M, Owusu-Agye S, Chandramohan D, Bonnet M, Guthmann JP, Clarke S, Barnes KL, Streat E, Katokele ST, Uusiku P, Agboghoroma CO, Elegba OY, Cisse B, A-Elbasit IE, Giha HA, Kachur SP, Lynch C, Rwakimari JB, Chanda P, Hawela M, Sharp B, Naidoo I, Roper R. Multiple origins and regional dispersal of resistant dhps in Afrcian Plasmodium falciparum malaria. PLoS Med. 2009;6:e1000055. doi: 10.1371/journal.pmed.1000055.
    1. Bwijo B, Kaneko A, Takechi M, Zungu IL, Moriyama Y, Lum JK, Tsukahara T, Mita T, Takahashi N, Bergqvist Y, Björkman A, Kobayakawa T. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop. 2003;85:363–373. doi: 10.1016/S0001-706X(02)00264-4.
    1. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997;176:1590–1596. doi: 10.1086/514159.
    1. Ramharter M, Adegnika AA, Agnandji ST, Matsiegui PB, Grobusch MP, Winkler S, Graninger W, Krishna J, Yazdanbakhsh M, Mordmueller B, Lell B, Missinou MA, Mavoungou E, Issifou S, Kremsner PG. History and perspectives of medical research at the Albert Schweitzer Hospital in Lambaréné, Gabon. Wien Klin Wochenschr. 2007;11(Suppl 3):8–12.
    1. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dörnemann J, Pötschke M, Oyakhirome S, Kiessling GC, Necek M, Langin MU, Klouwenberg PK, Klopfer A, Naumann B, Altun H, Agnandji ST, Goesch J, Decker M, Salazar CL, Supan C, Kombila DU, Borchert L, Koster KB, Pongratz P, Adegnika AA, Glasenapp I, Issifou S, Kremsner PG. Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2007;196:1595–1602. doi: 10.1086/522160.
    1. Grobusch MP, Gabor JJ, Aponte JJ, Schwarz NG, Poetschke M, Doernemann J, Schuster K, Koester KB, Profanter K, Borchert LB, Kurth F, Pongratz P, Issifou S, Lell B, Kremsner PG. No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon. J Infect Dis. 2009;200:1658–1661. doi: 10.1086/647990.
    1. Classification of treatment outcome WHO 2005. accessed 12 February, 2007.
    1. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother. 2003;47:1347–1354. doi: 10.1128/AAC.47.4.1347-1354.2003.
    1. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg. 2003;68:133–139.
    1. Planche T, Krishna S, Kombila M, Engel K, Faucher JF, Ngou-Milama E, Kremsner PG. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg. 2001;65:599–602.
    1. Oyakhirome S, Issifou S, Pongratz P, Barondi F, Ramharter M, Kun JFJ, Missinou MA, Lell B, Kremsner PG. Fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria: A randomized controlled trial. Antimicrob Agents Chemother. 2007;51:1869–1871. doi: 10.1128/AAC.01448-06.
    1. Kun FJK, Lehman LG, Lell B, Schmidt-Ott R, Kremsner PG. Low-dose treatment with sulfadoxine -pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains. Antimicrob Agents Chemother. 1999;43:2205–2208.
    1. Mawili-Mboumba DP, Ekala MT, Lekoulou F, Ntoumi F. Molecular analysis of DHFR and DHPS genes in P. falciparum clinical isolates from the Haut-Ogooué region in Gabon. Acta Trop. 2001;78:231–240. doi: 10.1016/S0001-706X(01)00084-5.
    1. Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, Bakary M, Le Bras J, Deloron P. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J Antimicrob Chemother. 2003;52:43–49. doi: 10.1093/jac/dkg294.
    1. Metzger W, Mordmüller B, Graninger W, Bienzle U, Kremsner PG. Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicr Chemother. 1995;36:723–728. doi: 10.1093/jac/36.4.723.
    1. Lell B, Lehman LG, Schmidt-Ott JR, Sturchler D, Handschin J, Kremsner PG. Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine-pyrimethamine compared with equivalent doses of sulfadoxine-pyrimethamine or mefloquine alone. Am J TropMed Hyg. 1998;58:619–624.
    1. Deloron P, Mayombo J, Le Cardinal A, Mezui-Me-Ndong J, Bruzi-Baert C, Lekoulou F, Elissa N. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. Trans R Soc Trop Med Hyg. 2000;94:188–190. doi: 10.1016/S0035-9203(00)90272-4.
    1. Nsimba B, Guiyedi V, Mabika-Mamfoumbi M, Mourou-Mbina JR, Ngoungou E, Bouyou-Akotet M, Loembet R, Durand R, Le Bras J, Kombila M. Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: A randomized trial to guide national policy. Malar J. 2008;7:31. doi: 10.1186/1475-2875-7-31.
    1. Winkler S, Brandts C, Wernsdorfer WH, Graninger W, Bienzle U, Kremsner PG. Drug sensitivity of Plasmodium falciparum in Gabon. Activity correlations between various antimalarials. Trop Med Parasitol. 1994;45:214–218.
    1. Van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, Greenwood BM. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg. 1995;89:672–676. doi: 10.1016/0035-9203(95)90438-7.
    1. Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, Molyneux ME, Plowe CV, Smith PJ. Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2005;72:267–272.
    1. Ehrhardt S, Mockenhaupt FP, Agana-Nsiire P, Mathieu A, Anemana SD, Stark K, Otchwemah RN, Bienzle U. Efficacy of chloroquine in the treatment of uncomplicated Plasmodium falciparum malaria in northern Ghana. Ann Trop Med Parasitol. 2002;96:239–247. doi: 10.1179/000349802125000772.
    1. Bousema JT, Gouagna LC, Meutstege AM, Okech BE, Akim NI, Githure JL, Beier JC, Sauerwein RW. Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Trop Med Int Health. 2003;8:427–430. doi: 10.1046/j.1365-3156.2003.01047.x.
    1. Méndez F, Munoz A, Carrasquilla G, Jurado D, Arévalo-Herrera M, Cortese JF, Plowe CV. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidem. 2002;156:230–238. doi: 10.1093/aje/kwf030.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren